Apricoxib: Difference between revisions
Content deleted Content added
consistent citation formatting |
Entranced98 (talk | contribs) Importing Wikidata short description: "Chemical compound" |
||
| (5 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| verifiedrevid = |
| verifiedrevid = |
||
| IUPAC_name = 4-[2-(4-Ethoxyphenyl)-4-methyl-1''H''-pyrrol-1-yl]benzenesulfonamide |
| IUPAC_name = 4-[2-(4-Ethoxyphenyl)-4-methyl-1''H''-pyrrol-1-yl]benzenesulfonamide |
||
| image = |
| image = Apricoxib.svg |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| CAS_number = |
| CAS_number = 197904-84-0 |
||
| ATC_prefix = |
| ATC_prefix = |
||
| ATC_suffix = |
| ATC_suffix = |
||
| ATC_supplemental = |
| ATC_supplemental = |
||
| PubChem = 9820073 |
| PubChem = 9820073 |
||
| DrugBank = |
| DrugBank = DB12378 |
||
| ChemSpiderID = 7995822 |
| ChemSpiderID = 7995822 |
||
| UNII = 5X5HB3VZ3Z |
| UNII = 5X5HB3VZ3Z |
||
| Line 16: | Line 17: | ||
| ChEBI = |
| ChEBI = |
||
| ChEMBL = |
| ChEMBL = |
||
<!-- Legal status --> |
|||
| legal_status = Investigational |
|||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=19 | H=20 | N=2 | O=3 | S=1 |
| C=19 | H=20 | N=2 | O=3 | S=1 |
||
| molecular_weight = 356.4387 g/mol |
|||
| smiles = CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C |
| smiles = CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C |
||
| StdInChI = 1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23) |
| StdInChI = 1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23) |
||
| Line 25: | Line 28: | ||
}} |
}} |
||
'''Apricoxib''' is an experimental anticancer drug. It is a [[COX-2 inhibitor]] which is intended to improve standard therapy response in molecularly |
'''Apricoxib''' is an experimental anticancer drug and [[nonsteroidal anti-inflammatory drug]] (NSAID).<ref>{{cite web | url = https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74021&ns=ncit | work = NCI Thesaurus | publisher = National Cancer Institute | title = Apricoxib (Code C74021) }}</ref> It is a [[COX-2 inhibitor]] which is intended to improve standard therapy response in molecularly-defined models of [[pancreatic cancer]].<ref>{{cite journal | vauthors = Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, Schwarz RE, Burrows FJ, Brekken RA | display-authors = 6 | title = Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer | journal = Clinical Cancer Research | volume = 18 | issue = 18 | pages = 5031–42 | date = September 2012 | pmid = 22829202 | pmc = 3777527 | doi = 10.1158/1078-0432.CCR-12-0453 }}</ref> It was also studied in clinical trials for [[non-small-cell lung cancer]].<ref>{{cite journal | vauthors = Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, Evans TL, Schneider BJ, Keresztes R, Rogers JS, de Mayolo JA, Feliciano J, Yang Y, Medeiros M, Zaknoen SL | display-authors = 6 | title = Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer | journal = Journal of Clinical Oncology | volume = 33 | issue = 2 | pages = 189–94 | date = January 2015 | pmid = 25452446 | pmc = 4890680 | doi = 10.1200/JCO.2014.55.5789 }}</ref> Development was abandoned in 2015 due to poor clinical trial results.<ref>{{cite web | title = Apricoxib | url = http://adisinsight.springer.com/drugs/800026002 | work = Adis Insight | publisher = Springer Nature Switzerland AG }}</ref> |
||
== See also == |
== See also == |
||
*[[Tilmacoxib]] |
*[[Tilmacoxib]] |
||
*[[ |
*[[Cimicoxib]] |
||
*[[NS-398]] |
*[[NS-398]] |
||
*[[Celecoxib]] |
*[[Celecoxib]] |
||
Latest revision as of 00:01, 25 January 2023
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H20N2O3S |
| Molar mass | 356.44 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Apricoxib is an experimental anticancer drug and nonsteroidal anti-inflammatory drug (NSAID).[1] It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly-defined models of pancreatic cancer.[2] It was also studied in clinical trials for non-small-cell lung cancer.[3] Development was abandoned in 2015 due to poor clinical trial results.[4]
See also
[edit]References
[edit]- ^ "Apricoxib (Code C74021)". NCI Thesaurus. National Cancer Institute.
- ^ Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, et al. (September 2012). "Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer". Clinical Cancer Research. 18 (18): 5031–42. doi:10.1158/1078-0432.CCR-12-0453. PMC 3777527. PMID 22829202.
- ^ Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, et al. (January 2015). "Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer". Journal of Clinical Oncology. 33 (2): 189–94. doi:10.1200/JCO.2014.55.5789. PMC 4890680. PMID 25452446.
- ^ "Apricoxib". Adis Insight. Springer Nature Switzerland AG.
 | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |